Abstract: Background/Objectives: While lecanemab (Leqembi) and several amyloid targeting therapies were approved for Alzheimer’s disease, questions remain on real-world …
Abstract: INTRODUCTION: Alzheimer's disease and related dementias (ADRD) remain a leading cause of morbidity and mortality. Poor cardiorespiratory fitness (CRF) has been identified …
Abstract: Background: We previously developed ancestry-specific risk scores for undiagnosed Alzheimer's disease and related dementias (ADRD) in Black and White American (BA and WA) …
Abstract: Introduction Aging United States Military Veterans are at an increased risk of developing dementia compared to the general population due to both military and …
Abstract: Background: Several amyloid targeting therapies have been approved for Alzheimer's disease (AD), including lecanemab (Leqembi). However, real-world implementation of …
Abstract: Introduction: Based on manual review of clinical notes of using the International Classification of Diseases, Tenth Revision coding, we evaluated the feasibility and …
Abstract: BackgroundIdentifying biomarkers of Alzheimer's disease (AD) is critical for early diagnosis and AD risk assessment.ObjectiveWe examined the hypothesis that the plasma …
Abstract: The VA Million Veteran Program (MVP) is a nationwide initiative that seeks to examine how genes influence health and behaviors in military veterans. An article by Merritt …
Abstract: Subjective cognitive decline (SCD) is an early risk marker for dementia. This study examined the 3-year incidence and predictors of SCD using the Medical Outcomes Study …
Abstract: Background: The age distribution and diversity of the VA Million Veteran Program (MVP) cohort make it a valuable resource for studying the genetics of Alzheimer's disease …
Abstract: Traumatic brain injuries (TBIs) may increase the risk for Alzheimer's disease (AD) and its neuropathological correlates, although the mechanisms of this relationship are …